The Weight Loss Stack

intermediateEst. $300–$700/mo12-16 weeks3 compounds
Written by dr-sarah-chen|Updated 2026-04-01|6 min read

A comprehensive weight loss protocol combining Semaglutide for appetite suppression with CJC-1295 and Ipamorelin for GH-mediated fat metabolism and lean mass preservation.

CompoundDoseFrequencyTimingRole
Semaglutide0.25-2.0mgOnce weekly (subcutaneous)Same day each week, any timeGLP-1 receptor agonist for appetite suppression, insulin sensitivity, and sustained weight loss
CJC-1295 (with DAC)1-2mg2-3x per week (subcutaneous)Evening, before bedSustained GHRH signaling for elevated baseline GH, fat metabolism, and recovery
Ipamorelin200-300mcgDaily (subcutaneous)Before bed on empty stomachPulsatile GH release for fat mobilization and lean mass preservation

Why This Stack Works

This protocol attacks fat loss through three complementary mechanisms:

  1. Semaglutide (a GLP-1 receptor agonist) dramatically reduces appetite and improves insulin sensitivity. Clinical trials demonstrate average weight loss of 15-20% of body weight over 68 weeks.

  2. CJC-1295 provides sustained GHRH signaling that elevates baseline growth hormone levels. This enhances lipolysis (fat breakdown) and supports metabolic rate during a caloric deficit.

  3. Ipamorelin triggers clean, pulsatile GH release that specifically targets fat metabolism while preserving lean muscle mass — the biggest challenge in any weight loss program.

The combination ensures you lose fat, not muscle, while experiencing dramatically reduced hunger.

Who This Protocol Is For

  • Individuals with significant weight to lose (20+ lbs) who have struggled with diet alone
  • Those seeking medically-supervised weight loss with peptide support
  • People who want to preserve muscle mass during aggressive fat loss
  • Anyone with insulin resistance or metabolic syndrome looking for pharmaceutical support

Semaglutide Titration Schedule

WeeksDoseNotes
1-40.25mg/weekInitiation phase — allows GI adaptation
5-80.5mg/weekMost users begin noticing significant appetite reduction
9-121.0mg/weekIncrease only if tolerated and weight loss has plateaued
13-16+1.5-2.0mg/weekMaximum therapeutic dose; not all users need this

Critical: Do not rush titration. Nausea, vomiting, and diarrhea are dose-dependent and typically manageable with slow titration.

Managing Semaglutide Side Effects

The most common side effects are gastrointestinal:

  • Nausea: Eat smaller, more frequent meals. Avoid high-fat foods. Ginger or ondansetron can help.
  • Constipation: Increase fiber and water intake. Magnesium citrate (400mg) at bedtime can help.
  • Reduced appetite: While this is the goal, ensure you still hit minimum protein targets. Protein shakes can help on low-appetite days.
  • Injection site reactions: Rotate injection sites. Mild redness typically resolves within 24 hours.

GH Peptide Timing Is Critical

Both CJC-1295 and Ipamorelin effectiveness depends on timing:

  • Fasted state: GH release is blunted by insulin. Always administer on an empty stomach.
  • Before bed: Nocturnal GH pulses are the largest natural pulses. Peptide dosing before sleep amplifies this window.
  • No carbs or food for 2 hours post-injection: Eating after injection will blunt the GH response.

Expected Results Timeline

  • Weeks 1-4: Gradual appetite reduction from Semaglutide. Initial GH optimization from peptides. Weight loss of 2-4 lbs.
  • Weeks 5-8: Significant appetite suppression. Improved energy and sleep from GH peptides. Weight loss accelerates to 1-2 lbs/week.
  • Weeks 9-12: Full stack synergy. Noticeable improvements in body composition — fat loss with muscle preservation. Cumulative weight loss of 10-20 lbs.
  • Weeks 13-16: Continued fat loss, especially visceral fat. Many users report significant improvements in metabolic markers (fasting glucose, triglycerides).

Safety Notes

  • Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
  • Report severe or persistent GI symptoms to your prescribing physician.
  • CJC-1295 and Ipamorelin may cause water retention, tingling, or mild hunger. These are typically transient.
  • Monitor thyroid function, as GLP-1 agonists may affect thyroid markers in rare cases.
  • This protocol should be supervised by a licensed healthcare provider.
  • Store all reconstituted peptides in the refrigerator and use within 30 days.

Related Goals

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any new treatment or protocol. Read our full medical disclaimer.